Tag Archives: hepatitis C

Friday’s sinking stocks and the reasons why (THS, CCOI, ACHN)

Posted on January 20, 2012 by Josie Middleton

In this report: Treehouse Foods (NYSE:THS), Cognet Communications Group (NASDAQ:CCOI) and Achillion Pharmaceuticals (NASDAQ:ACHN).

Treehouse Foods (NYSE:THS) is trading over 11 percent lower today after the company released a weaker than expected forecast for the fourth quarter as unseasonably warm …

Posted in Latest Headlines, Reports | Tagged Achillion Pharmaceuticals, ACHN, Analysts, CCOI, charged, Cognet Communications Group, company, copyright, earnings, expecting, FBI, Federal Bureau of Investigation, forecast, hepatitis C, infringement, Megaupload.com, NASDAQ, NASDAQ:ACHN, NASDAQ:CCOI, NYSE, NYSE:THS, outlook, quarter, seeking alpha, shares, THS, trading, Treehouse Foods, Wall Street | Comments Off

What the fuss Google, Oracle and Achillion Pharmaceuticals?

Posted on January 9, 2012 by Cameron White

In this report: Achillion Pharmaceuticals (NASDAQ:IDIX), Google (NASDAQ:GOOG) and Oracle (NASDAQ:ORCL).

Achillion Pharmaceuticals (NASDAQ:IDIX) and other Hepatitis C drug makers soared on Monday morning after Inhibitex (NASDAQ:INHX) became a $2.5 billion acquisition target for Bristol Myers Squibb (NYSE:BMY). The move, …

Posted in Latest Headlines, Reports | Tagged Achillion Pharmaceuticals, acquisition, Analysts, BMO Capital, BMY, Bristol-Myers Squibb, CEO, downgrade, drug, financial, firm, GOOG, Google, hepatitis C, IDIX, Inhibitex, investment, investors, Motorola Mobility Holdings, NASDAQ, nasdaq:goog, NASDAQ:IDIX, NASDAQ:ORCL, Oracle, ORCL, quarter, rating, report, sales, smartphone, treatments | Comments Off

What’s up Idenix Pharmaceuticals, Vivus and Broadcom?

Posted on January 9, 2012 by Martin Timble

In this report: Idenix Pharmaceuticals (NASDAQ:IDIX), Broadcom Corp. (NASDAQ:BRCM) and Vivus (NASDAQ:VVUS).

Idenix Pharmaceuticals (NASDAQ:IDIX) and Hepatitis C drug maker soared on Monday morning after Inhibitex (NASDAQ:INHX) became a $2.5 billion acquisition target for Bristol Myers Squibb (NYSE:BMY). The …

Posted in Latest Headlines, Reports | Tagged Analysts, BMY, BRCN, Bristol-Myers Squibb, Broadcom Corp., Buy, contraindication, Deutsche Bank, drug, FDA, firm, hepatitis C, Idenix Pharmaceuticals, IDIX, Inhibitex, INHX, investment, market, NASDAQ, NASDAQ:BRCM, NASDAQ:IDIX, NASDAQ:INHX, NASDAQ:VVUS, NYSE, NYSE:BMY, obesity, Qnexa, rating, upgrade, Vivus, VVUS | Comments Off

Soaring stocks and the reasons why (INHX, SMSI, RL)

Posted on January 9, 2012 by Josie Middleton

In this report: Inhibitex (NASDAQ:INHX), Smith Micro Software (NASDAQ:SMSI) and Polo Ralph Lauren (NYSE:RL).

Inhibitex (NASDAQ:INHX) shares soared by more than 140 percent today after the company became a $2.5 billion acquisition target for Bristol Myers Squibb (NYSE:BMY). The …

Posted in Latest Headlines, Reports | Tagged acquistion, approved, Bristol-Myers Squibb, Buy, CEO, company, conviction buy list, Goldman Sachs, growth, GS, hepatitis C, Inhibitex, INHX, investment, NASDAQ, NASDAQ:INHX, NASDAQ:SMSI, NYSE, NYSE:BMY, NYSE:GS, NYSE:RL, Polo Ralph Lauren, rating, report, RL, Smith Micro Software, SMSI, Sprint, Target, treatments, upgrade | Comments Off

What the fuss Affymax, Idenix Pharmaceuticals and Cameron International?

Posted on December 16, 2011 by Josie Middleton

In this report: Affymax (NASDAQ:AFFY), Idenix Pharmaceuticals (NASDAQ:IDIX) and Cameron International Corp. (NYSE:CAM).

Affymax (NASDAQ:AFFY) has dropped by more than 10 percent today after the company announced yesterday after the markets closed that it has decided not to commercialize peginesatide …

Posted in Latest Headlines, Reports | Tagged AFFY, Affymax, BP, CAM, Cameron International Corp., commercialization, company, deepwater horizon, developing, hepatitis C, Idenix Pharmaceuticals, IDIX, investors, killed, macondo, markets, NASDAQ, NASDAQ:AFFY, NASDAQ:IDIX, NASDAQ:VRUS, NYSE, NYSE:CAM, Peginesatide, Pharmasset, report, rights, spill, Takeda, treatments, VRUS, well | Comments Off

Big time losers and the reasons why (INHX, QTWW, STEM)

Posted on December 16, 2011 by Cameron White

In this report: Inhibitex (NASDAQ:INHX), Quantum Fuel Systems Technologies (NASDAQ:QTWW) and StemCells (NASDAQ:STEM).

Inhibitex (NASDAQ:INHX) as well as other companies developing hepatitis C virus treatments dropped lower on Friday after Pharmasset (NASDAQ:VRUS) stated that it will amend the design of …

Posted in Latest Headlines, Reports | Tagged common stock, company, corporate, gross proceeds, hepatitis C, Inhibitex, INHX, investors, NASDAQ:INHX, NASDAQ:QTWW, NASDAQ:STEM, NASDAQ:VRUS, offering, Pharmasset, Phase 2b, public offering, QTWW, Quantum, Quantum Fuel Systems Technologies, STEM, StemCells, trading, treatments, trial, unit, VRUS, warrant | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.